730 results on '"Domènech, E."'
Search Results
52. Disease severity in familial cases of IBD
53. Construcción de un modelo de cálculo y registro del percentil de peso neonatal
54. 20598. ANGIOGÉNESIS EN LA NEUROTOXICIDAD PERIFÉRICA INDUCIDA POR QUIMIOTERAPIA (NPIQ): EXPLORANDO EL VEGF CIRCULANTE COMO BIOMARCADOR DEL DESARROLLO Y RECUPERACIÓN DE LA NPIQ
55. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study
56. DOP081 Genital granulomatosis in Crohn’s disease: results of the ECCO CONFER study
57. N032 Impact of pain due to subcutaneous administration of a biological drug
58. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
59. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients
60. Editorial: therapeutic drug monitoring for anti‐TNF agents—has it all been said?
61. P706 Caracterization of de novo inflammatory bowel disease (IBD) diagnosed in immigrants migrating from low to high prevalence areas of IBD: a case-control study
62. P583 Trends in endoscopy management after surgery in a national cohort of Spanish Crohnʼs disease patients. Results from PRACTICROHN study
63. P603 Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohnʼs disease. Results from the PRACTICROHN study
64. P562 Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
65. P480 Characteristics of drug-induced lupus 2° to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF
66. P367 The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-making
67. DOP039 Postoperative infectious complications in Crohnʼs disease: results from PRACTICROHN study
68. OP013 Disease management and outcomes of patients with Crohnʼs disease at high risk of recurrence. Results from PRACTICROHN study
69. Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 × 109/L monoclonal lymphocytes better identifies subgroups with different outcomes
70. Safety assessment of smoked fish related to Listeria monocytogenes prevalence using risk management metrics
71. P1260: UNRAVELING THE GENETICS OF TRANSFORMED SPLENIC MARGINAL ZONE LYMPHOMA
72. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
73. Implementation and effectiveness of the HACCP and pre-requisites in food establishments
74. ENDOSCOPIC FULL-THICKNESS RESECTION OF A DUODENAL GIST WITH EXTRALUMINAL COMPONENT BY NOTES: TRACTION AND SUTURES
75. Prevalence and outcomes of acute-on-chronic liver failure among cirrhotic patients admitted for an acute decompensation
76. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
77. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
78. Exposure Assessment based on a combination of event and fault tree analyses and predictive modelling
79. Quantification of risk to company’s incomes due to failures in food quality
80. DOP78 Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
81. P289 Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project
82. POSC48 Cost-Effectiveness Analysis of Ferric Carboxymaltose Versus Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Spain
83. DOP05 Morbid obesity, a new susceptibility factor for developing Inflammatory Bowel Disease. Results of a population-based study
84. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
85. An approach for assessing CCP effectiveness in food production applications by predictive QRA modelling
86. Fetal and Neonatal Habituation in Infants of Diabetic Mothers
87. A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection
88. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry
89. Assessing the effectiveness of critical control points to guarantee food safety
90. Noninvasive assessment of liver fibrosis in Crohn's disease patients exposed to methotrexate
91. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry
92. Dietary habits in patients with fibromyalgia: A cross-sectional study
93. P022 Pathologic involvement of the farnesoid X receptor/fibroblast growth factor 19 axis to the Crohn’s disease early postsurgical recurrence
94. P671 Effect of genetic polymorphisms in the folate pathway on the efficacy and safety of methotrexate in Crohn’s disease
95. P262 Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry
96. P630 Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)
97. DOP31 Management and outcome of postoperative Crohn’s Disease in the elderly as compared to young adults: Data from Eneida registry
98. Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU
99. P678 Definition of a microbial signature as a predictor of post-surgical recurrence in patients with Crohn’s disease
100. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.